News

BenevolentAI announces agreement with leading healthcare company to leverage BenevolentAI’s technology platform

  • Framework collaboration agreement with Novartis across multiple drug programmes
  • Enables interrogation of clinical trial data sets using BenevolentAI's data integration and machine learning technologies
  • Collaboration starts immediately

BenevolentAI today announced that it has signed a Framework Collaboration Agreement with Novartis Pharma AG (“Novartis”) to leverage BenevolentAI’s technology platform to interrogate clinical trial and experimental data. This collaboration programme will be led by the Precision Medicine Team within Novartis Global Drug Development. The two companies will investigate indications and responder group(s) for oncology assets currently in clinical development.

Under the terms of the agreement, BenevolentAI will apply its technology designed to enable better data-driven decisions to find new ways to treat disease and personalise drugs for patients. The Benevolent Platform® ingests molecular, clinical, pharmacological data and scientific literature, to derive contextual relationships in the data between genes, diseases, drugs and biological pathways leading to the proposal of novel/optimal drug targets. The Platform supports scientists in the design and optimisation of the right drug molecule for a unique patient population.  

Joanna Shields, CEO of BenevolentAI said, “We’re excited to be entering into this important collaboration with Novartis. While the same drug may be prescribed for all patients diagnosed with a disease, often the underlying cause of the disease varies from patient to patient.  Consequently, many experience little therapeutic benefit. This initial project with Novartis in oncology will see the application of our AI and machine learning technology to stratify patients and gain a better understanding of patient and disease heterogeneity to more precisely target medicines for patients who need them.”


About BenevolentAI

BenevolentAI, founded in 2013, is an AI company developing and applying advanced technologies to accelerate the journey from data to  medicine. The company combines the power of computational medicine and advanced AI with the principles of open systems and cloud computing to transform the way drugs are designed, developed, tested and brought to market.  The company has developed the ‘Benevolent Platform’, the world’s only end-to-end computational and experimental platform for drug discovery that’s spans data ingestion to clinical development

BenevolentAI is HQ’d in London with a research facility in Cambridge (UK) and further offices in New York and Belgium. BenevolentAI has active R&D drug programmes from discovery to PhaseIIb in disease areas such as ALS, Parkinson’s, Ulcerative Colitis and Sarcopenia.

More Posts

You Might Also Like

News
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
News
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022
Blog
Building the data foundations to accelerate drug discovery
Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
Sep 22, 2022
News
Analyst / Investor Event and Interim Results
BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.
Sep 16, 2022
Video
Text & Data Mining in Drug Discovery: A Conversation with Springer Nature
Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.
Sep 2, 2022
News
Notice of Interim Results and Analyst / Investor Event
BenevolentAI will announce interim results on the 27th of September and hold an analyst and investor event on the same day. Find out more.
Aug 26, 2022